Guidelines for the clinical use of probiotics' and its limited value for gastrointestinal disorders

Khaled M. Hassan, Abdulrahman S. Alahmari, Omar M. Alfaifi, Abdulsalam A. Alshehri, Abdusalam S. Alqhtani, Rahaf A. Bagais, Obai T. Mesawa, Bader A. Alzahrani, Abdulrauf K. Al Senan, Raniya T. Ashi, Safwan A. Mubarki, Mohammed A. Alhamyani, Mohammad S. Almarri


Changes in gut microbiota composition are associated with a variety of gastrointestinal disorders, including inflammatory bowel diseases, diarrhoea and hepatic diseases. Probiotics, which are live microorganisms which can provide the host a health benefit when ingested, are widely used as a treatment to treat these gastrointestinal (GI) conditions by changing the microbiota's composition or behaviour. This analysis aimed to address show probiotics' minimal utility for GI conditions guidelines. The researcher used several papers and reviews from before. The findings of this study are a compilation of previous research, and Cochrane's systematic analysis of probiotics for GI disorders indicates that probiotics may have beneficial effects on diarrheal conditions and associated gastrointestinal symptoms. Finally, updated systematic reviews are required to reflect the entirety of existing research on probiotic treatments in the study. The results from the presented analysis would help to provide more reliable guidelines for the clinical use of probiotics' and its limited value for gastrointestinal disorders and recognize gaps in GI related probiotic research.


Gastrointestinal, Probiotics, Medical conditions

Full Text:



Brahe LK, Astrup A, Larsen LH. Can we prevent obesity-related metabolic diseases by dietary modulation of the gut microbiota?. Adv Nutr. 2016;7(1):90-101.

Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and alternative medicines used by patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):415-29.‏

Elzouki AN. Probiotics and liver disease: Where are we now and where are we going?. J Clin Gastroenterol. 2016;50:S188-90.‏

Gómez-Gallego C, Pohl S, Salminen S, De Vos WM, Kneifel W. Akkermansia muciniphila: a novel functional microbe with probiotic properties. Beneficial Microbes. 2016;7(4):571-84.‏

Parker EA, Roy T, D'Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition. 2018;45:125-34.‏

Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Mende DR. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.‏

Sarah HY, Jernigan JA, McDonald LC. Prevalence of probiotic use among inpatients: a descriptive study of 145 US hospitals. Am J Infection Control. 2016;44(5):548-53.‏

Senok AC, Ismaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect. 2005;11(12):958-66.‏

Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Family Physician. 2017;96(3):170-8.‏

Pajunen P, Rissanen H, Harkanen T, Jula A, Reunanen A, Salomaa V. The metabolic syndrome as a predictor of incident diabetes and cardiovascular events in the Health 2000 Study. Diabetes Metab. 2010;36:395-401.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55-60.

Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541-6.

Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013;62:1112-21.

Vulevic J, Juric A, Tzortzis G, Gibson GR. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr. 2013;143:324–31.

Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585-8.

Koeppen BM, Stanton BA. eds. Berne & Levy Physiology. 7th ed. Canada: Elsevier; 2008.

Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link?. Obes Rev. 2011;12:449-58.

Forsythe P, Bienenstock J. Immunomodulation by commensal and probiotic bacteria. Immunol Invest. 2010;39:429-48.